A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis
Latest Information Update: 29 Nov 2023
Price :
$35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms OCTAVE; OCTAVE Sustain
- Sponsors Pfizer
- 17 Oct 2023 Results of matching-adjusted indirect comparisons (MAIC) of the efficacy and safety of Upadacitinib vs Vedolizumab, Ustekinumab and Tofacitinib in the phase 3 maintenance studies U-ACHIEVE, GEMINI-1, UNIFI & OCTAVE Sustain, presented at the 31st United European Gastroenterology Week.
- 17 Oct 2023 Results of post hoc analysis assessing baseline factors associated with symptomatic remission at Week 8 in patients who received tofacitinib 10 mg twice daily (BID) in OCTAVE Induction 1&2 (NCT01465763; NCT01458951) and compare the efficacy of tofacitinib 5 and 10 mg BID after 52 weeks of maintenance treatment in OCTAVE Sustain presented at the 31st United European Gastroenterology Week
- 17 Oct 2023 Results assessing final safety analyses from the tofacitinib UC ((NCT00787202; NCT01465763; NCT01458951; NCT01458574,NCT01470612, NCT03281304) presented at the 31st United European Gastroenterology Week